Statistics from Altmetric.com
Are the second-generation antipsychotic drugs (SGAs) different in their capacity to induce extrapyramidal side effects (EPS)?
Primary outcome: use of antiparkinson medication at least once (used as a global measure for EPS).
Systematic review and meta-analysis.
The register of the Cochrane Schizophrenia Group was searched up to May 2007, and MEDLINE was searched up to July 2009, with no language restrictions. The search terms used were all 36 possible combinations of the names of the SGAs, including trade names. The SGAs in question were amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine. Manufacturers were contacted for details of published and unpublished studies, and study authors were contacted for missing data in their studies.
Study selection and analysis
Blinded randomised controlled trials (RCTs) directly comparing different orally administered SGAs for the treatment of schizophrenia or related disorders. Only studies meeting the quality criteria A (adequate …
Sources of funding Technische Universitat München; German Federal Ministry of Education and Research; National Institute of Mental Health, Advanced Center for Intervention and Services Research Center; Maryland Psychiatric Research Center; EliLilly; Sanofi-Aventis.
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.